Holen Sie sich die Stockscreener-App
30.37
0.95%
-0.29
Handel nachbörslich:
30.35
-0.02
-0.07%
Schlusskurs vom Vortag:
$30.66
Offen:
$30.8
24-Stunden-Volumen:
652.89K
Relative Volume:
0.48
Marktkapitalisierung:
$3.22B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-150.70M
KGV:
-19.59
EPS:
-1.55
Netto-Cashflow:
$-125.67M
1W Leistung:
+11.70%
1M Leistung:
+25.86%
6M Leistung:
+126.81%
1J Leistung:
+17.49%
1-Tages-Spanne:
$29.38
$30.81
1-Wochen-Bereich:
$27.78
$31.26
52-Wochen-Spanne:
$10.60
$31.26
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Firmenname
Edgewise Therapeutics Inc
Sektor
Branche
Telefon
720-262-7002
Adresse
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
30.37 | 3.25B | 0 | -150.70M | -125.67M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-25 | Eingeleitet | Goldman | Neutral |
| 2025-07-30 | Eingeleitet | Raymond James | Strong Buy |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-30 | Eingeleitet | Guggenheim | Buy |
| 2025-04-02 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-01-22 | Eingeleitet | Stifel | Hold |
| 2024-11-22 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-07 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2022-08-25 | Herabstufung | Goldman | Neutral → Sell |
| 2022-04-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-28 | Eingeleitet | Goldman | Neutral |
Alle ansehen
Edgewise Therapeutics Inc Aktie (EWTX) Neueste Nachrichten
EWTX: Phase III readouts and new cardiac programs drive momentum, with strong commercial readiness - TradingView
Assessing Edgewise Therapeutics (EWTX) Valuation After Recent Share Price Momentum - Yahoo Finance
Published on: 2026-02-11 09:46:19 - mfd.ru
Piper Sandler Sticks to Their Buy Rating for Edgewise Therapeutics (EWTX) - The Globe and Mail
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: A Biotech Gem with 26% Upside Potential - DirectorsTalk Interviews
Edgewise Therapeutics stock hits 52-week high at $30.26 By Investing.com - Investing.com South Africa
Analyst Reiterates Bullish Stance on Edgewise Stock - Intellectia AI
Why Edgewise Therapeutics Stock Crushed the Market on Monday - AOL.com
Edgewise Therapeutics (NASDAQ:EWTX) Sets New 12-Month HighTime to Buy? - MarketBeat
Why Edgewise Therapeutics Stock Crushed the Market on Monday - The Motley Fool
Piper Sandler reiterates Overweight rating on Edgewise Therapeutics stock By Investing.com - Investing.com Canada
Piper Sandler reiterates Overweight rating on Edgewise Therapeutics stock - Investing.com
Federated Hermes Inc. Decreases Stock Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Downgraded by Wall Street Zen to Sell - Defense World
Growth Recap: Can Edgewise Therapeutics Inc expand its profit margins2025 Earnings Impact & Weekly Stock Breakout Alerts - baoquankhu1.vn
Braveheart Bio names Marc Evanchik CSO - The Pharma Letter
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 - PR Newswire
Edgewise Therapeutics (EWTX): Analyst Consensus Reveals A 32% Upside Potential - DirectorsTalk Interviews
Dow Update: What analysts say about Edgewise Therapeutics Inc stockJuly 2025 Review & AI Enhanced Execution Alerts - baoquankhu1.vn
Edgewise Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules - 富途牛牛
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Short Interest Down 19.4% in January - MarketBeat
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire
Y Intercept Hong Kong Ltd Invests $929,000 in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Responsive Playbooks and the EWTX Inflection - Stock Traders Daily
EPS Watch: Is Edgewise Therapeutics Inc exposed to currency risksRisk Management & Low Risk Growth Stock Ideas - baoquankhu1.vn
Returns Recap: Will Edgewise Therapeutics Inc benefit from current market trendsWeekly Risk Summary & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Edgewise Therapeutics Reports Q3 2025 Financial Results - MSN
Campbell & CO Investment Adviser LLC Lowers Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Edgewise Therapeutics director sells $3.39 million in shares By Investing.com - Investing.com India
Edgewise Therapeutics(EWTX.US) Director Sells US$3.4 Million in Common Stock - 富途牛牛
Retail Trends: Will Edgewise Therapeutics Inc stock hit new highs in YEAR2025 Market WrapUp & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Wall Street Zen Upgrades Edgewise Therapeutics (NASDAQ:EWTX) to "Hold" - MarketBeat
Insider Sell: Badreddin Edris Sells 115,471 Shares of Edgewise Therapeutics Inc (EWTX) - GuruFocus
Edgewise Therapeutics (NASDAQ:EWTX) Director Sells $3,399,466.24 in Stock - MarketBeat
Edgewise Therapeutics director sells $3.39 million in shares - Investing.com
Retail Trends: Is Edgewise Therapeutics Inc trading at a discountJuly 2025 Institutional & Real-Time Volume Triggers - baoquankhu1.vn
Understanding the Setup: (EWTX) and Scalable Risk - Stock Traders Daily
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: A 39% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Edgewise Therapeutics, Inc. (EWTX) outlines priorities for 2026 - MSN
Is Edgewise Therapeutics (EWTX) Quietly Redefining Its Risk Profile With an Integrated Muscle-Heart Strategy? - Sahm
Medpace and Edgewise Therapeutics Advance Becker Muscular Dystrophy Study - MSN
Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 6.4%Time to Sell? - MarketBeat
Edgewise Therapeutics, Inc. (EWTX) Outlines Priorities For 2026 - Insider Monkey
14 Best Booming Stocks to Buy Right Now - Insider Monkey
A Look At Edgewise Therapeutics (EWTX) Valuation After Detailed 2026 Clinical Milestone Update - Sahm
Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX - TechStock²
Edgewise Therapeutics (NASDAQ:EWTX) Shares Up 7%Should You Buy? - MarketBeat
Technical Analysis: Is Edgewise Therapeutics Inc subject to activist investor interest2025 Analyst Calls & Risk Managed Investment Entry Signals - baoquankhu1.vn
Why Edgewise Therapeutics (EWTX) Is Up 8.8% After Mapping Its 2026 Rare-Disease Pipeline Priorities – And What's Next - Yahoo Finance
A Look At Edgewise Therapeutics (EWTX) Valuation After J P Morgan Clinical Pipeline Update - Yahoo Finance
Finanzdaten der Edgewise Therapeutics Inc-Aktie (EWTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Edgewise Therapeutics Inc-Aktie (EWTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Edris Badreddin | Director |
Jan 21 '26 |
Sale |
29.44 |
115,471 |
3,399,466 |
19,820 |
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):